Literature DB >> 20934397

Recent advances in the understanding of the role of the endocannabinoid system in liver diseases.

Li Huang1, Matthew A Quinn, Gabriel A Frampton, Lessie Eric Golden, Sharon DeMorrow.   

Abstract

Endocannabinoids are ubiquitous signalling molecules that exert their effects through a number of specific cannabinoid receptors. Recent studies have indicated that this endocannabinoid system is involved in the pathophysiological processes associated with both acute and chronic liver diseases as well as in the complications that arise from these diseases such as hepatic encephalopathy and cardiac problems. Targeting this signalling system has been useful in ameliorating some of the symptoms and consequences in experimental models of these liver diseases. This review summarises the recent advances into our knowledge and understanding of endocannabinoids in liver diseases and highlights potential novel therapeutic strategies that may prove useful to treat these diseases.
Copyright © 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20934397      PMCID： PMC3033442          DOI： 10.1016/j.dld.2010.08.010

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN： 1590-8658            Impact factor:   4.088


  67 in total

1.  Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation.

Authors:  I Galve-Roperh; C Sánchez; M L Cortés; T Gómez del Pulgar; M Izquierdo; M Guzmán
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

Review 2.  The endocannabinoid signalling system: biochemical aspects.

Authors:  Tiziana Bisogno; Alessia Ligresti; Vincenzo Di Marzo
Journal:  Pharmacol Biochem Behav       Date:  2005-06       Impact factor: 3.533

Review 3.  Endocannabinoids in liver disease and hepatic encephalopathy.

Authors:  Iddo Magen; Yosefa Avraham; Elliot Berry; Raphael Mechoulam
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

4.  Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism.

Authors:  L Ruiz; A Miguel; I Díaz-Laviada
Journal:  FEBS Lett       Date:  1999-09-24       Impact factor: 4.124

Review 5.  Anandamide transport: a critical review.

Authors:  Sherrye T Glaser; Martin Kaczocha; Dale G Deutsch
Journal:  Life Sci       Date:  2005-08-19       Impact factor: 5.037

6.  Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats.

Authors:  Seyed Ali Gaskari; Hongqun Liu; Leila Moezi; Yang Li; Soon Koo Baik; Samuel S Lee
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

7.  Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice.

Authors:  Yosefa Avraham; Eran Israeli; Ezra Gabbay; Avital Okun; Olga Zolotarev; Isable Silberman; Vera Ganzburg; Yossi Dagon; Iddo Magen; Lia Vorobia; Orit Pappo; Raphael Mechoulam; Yaron Ilan; Elliot M Berry
Journal:  Neurobiol Dis       Date:  2005-08-15       Impact factor: 5.996

Review 8.  Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis.

Authors:  Leila Moezi; Seyed Ali Gaskari; Samuel S Lee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-08-14       Impact factor: 4.052

9.  The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway.

Authors:  Sharon DeMorrow; Heather Francis; Eugenio Gaudio; Julie Venter; Antonio Franchitto; Shelley Kopriva; Paolo Onori; Romina Mancinelli; Gabriel Frampton; Monique Coufal; Brett Mitchell; Bradley Vaculin; Gianfranco Alpini
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-10-02       Impact factor: 4.052

Review 10.  Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects.

Authors:  A A Izzo; M Camilleri
Journal:  Gut       Date:  2008-04-08       Impact factor: 23.059
View more
  8 in total

Review 1.  Cannabis for Rheumatic Disease Pain: a Review of Current Literature.

Authors:  William Benjamin Nowell; Kelly Gavigan; Stuart L Silverman
Journal:  Curr Rheumatol Rep       Date:  2022-04-29       Impact factor: 4.686

Review 2.  Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Authors:  Roger G Pertwee
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

3.  Cannabinoid receptor signaling regulates liver development and metabolism.

Authors:  Leah Y Liu; Kristen Alexa; Mauricio Cortes; Stephanie Schatzman-Bone; Andrew J Kim; Bani Mukhopadhyay; Resat Cinar; George Kunos; Trista E North; Wolfram Goessling
Journal:  Development       Date:  2016-02-15       Impact factor: 6.868

4.  Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model.

Authors:  Dongmei Shi; Xi Zhan; Xiaofeng Yu; Minglei Jia; Ying Zhang; Jianfeng Yao; Xiaona Hu; Zhijun Bao
Journal:  Lipids Health Dis       Date:  2014-11-18       Impact factor: 3.876

5.  Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells.

Authors:  Roberta Montalbano; Birgit Honrath; Thaddeus Till Wissniowski; Moritz Elxnat; Silvia Roth; Matthias Ocker; Karl Quint; Yuri Churin; Martin Roederfeld; Dirk Schroeder; Dieter Glebe; Elke Roeb; Pietro Di Fazio
Journal:  Oncotarget       Date:  2016-04-12

Review 6.  Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents.

Authors:  Daniel A Ladin; Eman Soliman; LaToya Griffin; Rukiyah Van Dross
Journal:  Front Pharmacol       Date:  2016-10-07       Impact factor: 5.810

7.  Suppression of CB1 cannabinoid receptor by lentivirus mediated small interfering RNA ameliorates hepatic fibrosis in rats.

Authors:  Si-Wen Chen; Ben-Yan Wu; Shi-Ping Xu; Ke-Xing Fan; Li Yan; Yuan Gong; Jun-Bao Wen; Dao-Hong Wu
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

8.  Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis.

Authors:  Laurence Brunet; Erica E M Moodie; Kathleen Rollet; Curtis Cooper; Sharon Walmsley; Martin Potter; Marina B Klein
Journal:  Clin Infect Dis       Date:  2013-06-28       Impact factor: 9.079
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.